Reports & Insights

The Pharmaceutical Launch Excellence Summit Europe 2026 is where the industry's most influential launch leaders converge to decode what truly drives commercial success today. In a closed‑door, practitioner‑only environment, senior leaders from Pfizer, Takeda, Novo Nordisk, Biogen, Sandoz, CSL, BMS and more share the real strategies, frameworks, and lessons shaping Europe's most competitive launches across oncology, immunology, obesity, rare diseases, and biosimilars.

Across three days of case studies, workshops, a focus day and cross‑functional roundtables, you'll gain practical, repeatable approaches to accelerate adoption, strengthen launch readiness, navigate evolving policy and access pressures, and embed AI‑powered decision‑making into your launch strategy. If you're responsible for delivering measurable launch impact, #PHLEX is the one event you cannot afford to miss.

Learn how pharmaceutical companies are using AI to improve patient targeting, forecasting, market access, and launch execution. This practical insight brief explores the AI capabilities helping launch teams make faster decisions, identify opportunities earlier, and improve commercial performance.

You'll learn:

• How AI improves patient identification and segmentation
• Smarter forecasting and scenario planning techniques
• AI applications in pricing and market access
• Early detection of market and competitive signals
• Real-time launch performance monitoringStrategies for better commercial decision-making

Download your complimentary copy of the industry report today for an in-depth analysis of the trends, challenges and market forces shaping pharmaceutical launches. Explore the latest insights on market access, pricing and reimbursement, AI, launch execution, and evolving regulatory requirements, alongside real-world examples from leading pharmaceutical organisations.

• Why up to two-thirds of pharmaceutical launches fail to meet expectations and the common execution gaps separating launch readiness from launch success.
• How the first 6-12 months now determine long-term launch performance, with early access, adoption and payer decisions becoming increasingly difficult to reverse.
• The impact of the EU HTA Regulation and Joint Clinical Assessments, and what launch teams need to do now to prepare evidence strategies for a changing European market access landscape.
• How pricing, reimbursement and access pressures are reshaping launch strategy across Europe and the US, from Medicare negotiations to increasing payer scrutiny and value-based assessments.
• The rise of obesity, oncology and specialty therapies, with oncology spend forecast to exceed $440 billion globally by 2029 and obesity medicines projected to reach up to $280 billion by 2030.
• Practical AI use cases already improving launch performance, including forecasting, omnichannel optimisation, field enablement, medical insight generation and early signal detection.
• How leading organisations are evolving launch operating models, moving from milestone-based launch planning to continuous launch performance management.
• Real-world lessons from companies including AstraZeneca, Roche, Novartis, Teva and Sandoz on evidence generation, market access, launch sequencing and supply resilience
  

The 2026 State of Pharma Launch Excellence Industry Report is here

With rising R&D costs, limited access to healthcare professionals, and fierce competition across all therapeutic areas, pharma leaders are facing more pressure than ever. This comprehensive 60+ page report dives deep into the challenges, market trends, and industry practices shaping the future of pharma launch strategy.

Download your complimentary copy today and equip your team with the insights needed to launch smarter, faster, and more effectively >>

The Pharmaceutical Launch Excellence Summit (PHLEX) 2025 brought together senior pharma leaders to explore the future of launch excellence amid growing complexity. For key takeaways, audience insights, agenda highlights, testimonials, and more, download the Post Show Report now >>

Explore Pharma Launch Excellence: 2025 vs 2026

Discover how pharmaceutical launch strategies are evolving with our latest comparative analysis. This report highlights key market trends, emerging therapeutic areas, and the factors behind launch failures and successes, giving you actionable insights to plan effectively for 2026. Read the full analysis now

AI is rapidly redefining how pharmaceutical companies plan, execute, and optimise drug launches. This exclusive insight brief explores the growing impact of AI (particularly Generative AI) across every stage of the launch lifecycle.

From early discovery to post-launch performance, AI is enabling faster timelines, smarter resource allocation, and more personalised engagement strategies.

Access the Insight Brief now >>

Pharma Launch Readiness Checklist: Your 10-Step Guide to Pharma Launch Success

Is your pharma launch ready? This concise checklist distills the key insights from our 2025 Global State of Pharma Launch Excellence Industry Report into a practical guide for launch leaders, brand teams, and cross-functional stakeholders. Learn how to navigate complexity, avoid common pitfalls, and drive long-term success, from strategy and market entry to post-launch performance. Download your copy now and future-proof your next launch>>

Relive the highlights from the inaugural Pharmaceutical Launch Excellence (PHLEX) Summit in London with our official Post Show Report.

Over 75 pharma launch leaders came together to share strategies on forecasting, cross-functional orchestration, digital transformation, and post-launch optimization. This report captures the key insights, success frameworks, and community energy that defined the event, plus a preview of what’s to come at the 2nd Annual PHLEX Summit this December.

Download your copy now and join the growing #PHLEX community driving better patient outcomes worldwide.

The pharmaceutical landscape is evolving rapidly, with more launches failing than ever before. This brand new report - the most detailed and accurate to date - provides a full update on the current state of pharmaceutical launches, examining why these failures are occurring, which specific launches are struggling, and what strategies companies are implementing to overcome these challenges. This comprehensive analysis names key drugs, organisations, and insights to help you navigate regulatory hurdles and position your launches for success in this evolving landscape. Download your complimentary copy now

Need approval to attend? We’ve got you covered

Getting sign-off to attend an industry-leading event can take time, but we’re here to make it easier.

Download our free, customisable Attendance Proposal Template to help you clearly communicate the value of attending the Pharmaceutical Launch Excellence Summit. It’s designed to streamline the approval process and highlight how this event supports your strategic goals.

Get your complimentary copy now

Dive into an exclusive interview with Sherif Elhaw, Pfizer's Launch Excellence Lead for Emerging Markets. With over two decades of experience in pharmaceuticals, Sherif shares his journey, the evolution of launch strategies, and the pivotal role of innovation in overcoming industry challenges. Gain valuable insights into navigating the complexities of product launches and discover how to harness critical thinking and data analytics for successful outcomes. Download this content to empower your approach to drug launches and stay ahead in the dynamic pharmaceutical landscape. Don't miss the opportunity to learn from a leader at the forefront of healthcare innovation!